Tenax Therapeutics, Inc. (TENX)
USD 5.77
(0.61%)
USD 5.77
(0.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -8.23 Million USD | 25.5% |
| 2022 | -11.05 Million USD | 66.23% |
| 2021 | -32.72 Million USD | -231.66% |
| 2020 | -9.86 Million USD | -15.34% |
| 2019 | -8.55 Million USD | -24.11% |
| 2018 | -6.89 Million USD | 25.12% |
| 2017 | -9.2 Million USD | 82.52% |
| 2016 | -52.65 Million USD | -255.35% |
| 2015 | -14.81 Million USD | 10.8% |
| 2014 | -16.61 Million USD | -220.12% |
| 2013 | -5.18 Million USD | 36.87% |
| 2012 | -8.22 Million USD | 22.18% |
| 2011 | -10.56 Million USD | -6.12% |
| 2010 | -9.95 Million USD | -19.02% |
| 2009 | -8.36 Million USD | -185.16% |
| 2008 | -2.93 Million USD | -65.46% |
| 2007 | -1.77 Million USD | 28.49% |
| 2006 | -2.47 Million USD | 7.67% |
| 2005 | -2.68 Million USD | -18.41% |
| 2004 | -2.26 Million USD | 0.27% |
| 2003 | -2.27 Million USD | 36.93% |
| 2002 | -3.6 Million USD | -80.03% |
| 2001 | -2 Million USD | -119.64% |
| 2000 | -911.59 Thousand USD | -13.95% |
| 1999 | -800 Thousand USD | 36.18% |
| 1998 | -1.25 Million USD | 33.94% |
| 1997 | -1.89 Million USD | 18.95% |
| 1996 | -2.34 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 3.79 Million USD | 213.71% |
| 2024 Q2 | -3.67 Million USD | -196.66% |
| 2023 Q4 | -3.34 Million USD | -257.79% |
| 2023 Q2 | 1.23 Million USD | -19.7% |
| 2023 FY | -8.23 Million USD | 25.5% |
| 2023 Q3 | 2.11 Million USD | 71.29% |
| 2023 Q1 | 1.53 Million USD | 107.87% |
| 2022 Q4 | -19.55 Million USD | -770.12% |
| 2022 Q1 | 2.71 Million USD | 184.65% |
| 2022 Q2 | 2.86 Million USD | 5.27% |
| 2022 FY | -11.05 Million USD | 66.23% |
| 2022 Q3 | 2.91 Million USD | 1.94% |
| 2021 Q3 | -3.8 Million USD | -293.55% |
| 2021 FY | -32.72 Million USD | -231.66% |
| 2021 Q4 | -3.21 Million USD | 15.53% |
| 2021 Q1 | -23.74 Million USD | -738.24% |
| 2021 Q2 | 1.96 Million USD | 108.27% |
| 2020 Q3 | -2.22 Million USD | -3.78% |
| 2020 Q4 | -2.83 Million USD | -27.33% |
| 2020 Q1 | -2.66 Million USD | 5.26% |
| 2020 FY | -9.86 Million USD | -15.34% |
| 2020 Q2 | -2.14 Million USD | 19.56% |
| 2019 Q1 | -1.66 Million USD | 25.39% |
| 2019 Q2 | -1.81 Million USD | -9.5% |
| 2019 FY | -8.55 Million USD | -24.11% |
| 2019 Q4 | -2.81 Million USD | -24.46% |
| 2019 Q3 | -2.26 Million USD | -24.22% |
| 2018 FY | -6.89 Million USD | 25.12% |
| 2018 Q3 | -1.55 Million USD | 17.72% |
| 2018 Q1 | 1.22 Million USD | 188.48% |
| 2018 Q2 | -1.88 Million USD | -254.44% |
| 2018 Q4 | -2.22 Million USD | -43.3% |
| 2017 Q1 | -3.49 Million USD | 90.74% |
| 2017 FY | -9.2 Million USD | 82.52% |
| 2017 Q4 | -1.38 Million USD | -5.48% |
| 2017 Q3 | -1.31 Million USD | 56.53% |
| 2017 Q2 | -3.01 Million USD | 13.85% |
| 2016 Q2 | -4.67 Million USD | 18.13% |
| 2016 Q4 | -37.77 Million USD | -739.31% |
| 2016 Q3 | -4.5 Million USD | 3.65% |
| 2016 FY | -52.65 Million USD | -255.35% |
| 2016 Q1 | -5.7 Million USD | -3.7% |
| 2015 FY | -14.81 Million USD | 10.8% |
| 2015 Q1 | -5.12 Million USD | -63.41% |
| 2015 Q2 | -3.11 Million USD | 39.2% |
| 2015 Q3 | -3.74 Million USD | -20.38% |
| 2015 Q4 | -5.5 Million USD | -46.74% |
| 2014 Q3 | -4.14 Million USD | -71.46% |
| 2014 Q2 | -2.41 Million USD | 76.93% |
| 2014 Q1 | -10.47 Million USD | -330.86% |
| 2014 FY | -16.61 Million USD | -220.12% |
| 2014 Q4 | -3.13 Million USD | 24.34% |
| 2013 Q3 | -2.11 Million USD | -33.01% |
| 2013 Q1 | -1.23 Million USD | 22.13% |
| 2013 FY | -5.18 Million USD | 36.87% |
| 2013 Q4 | -2.43 Million USD | -15.0% |
| 2013 Q2 | -1.58 Million USD | -28.27% |
| 2012 Q3 | -682.84 Thousand USD | 59.24% |
| 2012 Q4 | -1.59 Million USD | -133.07% |
| 2012 Q1 | -1.86 Million USD | 0.52% |
| 2012 Q2 | -1.67 Million USD | 10.12% |
| 2012 FY | -8.22 Million USD | 22.18% |
| 2011 Q4 | -1.87 Million USD | 8.78% |
| 2011 FY | -10.56 Million USD | -6.12% |
| 2011 Q3 | -2.05 Million USD | 15.4% |
| 2011 Q2 | -2.42 Million USD | 10.99% |
| 2011 Q1 | -2.72 Million USD | 0.97% |
| 2010 FY | -9.95 Million USD | -19.02% |
| 2010 Q1 | -2.24 Million USD | 18.88% |
| 2010 Q2 | -3.02 Million USD | -35.02% |
| 2010 Q3 | -2.05 Million USD | 32.08% |
| 2010 Q4 | -2.75 Million USD | -33.94% |
| 2009 Q1 | -1.7 Million USD | -76.61% |
| 2009 FY | -8.36 Million USD | -185.16% |
| 2009 Q4 | -2.76 Million USD | -6.62% |
| 2009 Q3 | -2.59 Million USD | -13.21% |
| 2009 Q2 | -2.29 Million USD | -34.61% |
| 2008 FY | -2.93 Million USD | -65.46% |
| 2008 Q4 | -963.54 Thousand USD | 58.91% |
| 2008 Q3 | -2.34 Million USD | 25.01% |
| 2008 Q2 | -3.12 Million USD | -121.43% |
| 2008 Q1 | -1.41 Million USD | -64.58% |
| 2007 Q1 | -385.54 Thousand USD | 19.29% |
| 2007 Q4 | -858.05 Thousand USD | -188.42% |
| 2007 FY | -1.77 Million USD | 28.49% |
| 2007 Q3 | -297.49 Thousand USD | 18.49% |
| 2007 Q2 | -364.97 Thousand USD | 5.33% |
| 2006 Q4 | -477.68 Thousand USD | -21.09% |
| 2006 FY | -2.47 Million USD | 7.67% |
| 2006 Q1 | -515.76 Thousand USD | 21.96% |
| 2006 Q2 | -514.69 Thousand USD | 0.21% |
| 2006 Q3 | -394.49 Thousand USD | 23.35% |
| 2005 Q3 | -686.06 Thousand USD | -11.4% |
| 2005 Q1 | -715.33 Thousand USD | 19.92% |
| 2005 Q4 | -660.92 Thousand USD | 3.66% |
| 2005 Q2 | -615.84 Thousand USD | 13.91% |
| 2005 FY | -2.68 Million USD | -18.41% |
| 2004 Q4 | -893.29 Thousand USD | -48.66% |
| 2004 Q1 | -524.67 Thousand USD | 35.66% |
| 2004 Q2 | -475.08 Thousand USD | 9.45% |
| 2004 FY | -2.26 Million USD | 0.27% |
| 2004 Q3 | -600.9 Thousand USD | -26.48% |
| 2003 Q1 | -343.19 Thousand USD | 27.54% |
| 2003 Q2 | -459.37 Thousand USD | -33.85% |
| 2003 Q3 | -467.63 Thousand USD | -1.8% |
| 2003 FY | -2.27 Million USD | 36.93% |
| 2003 Q4 | -815.52 Thousand USD | -74.39% |
| 2002 Q3 | -1.03 Million USD | -149.39% |
| 2002 FY | -3.6 Million USD | -80.03% |
| 2002 Q4 | -473.63 Thousand USD | 54.44% |
| 2002 Q2 | -416.88 Thousand USD | 79.0% |
| 2002 Q1 | -1.98 Million USD | -296.11% |
| 2001 FY | -2 Million USD | -119.64% |
| 2001 Q1 | -566.9 Thousand USD | -15.24% |
| 2001 Q2 | -562.87 Thousand USD | 0.71% |
| 2001 Q3 | -556.73 Thousand USD | 1.09% |
| 2001 Q4 | -501.11 Thousand USD | 9.99% |
| 2000 Q2 | -343.8 Thousand USD | 16.47% |
| 2000 Q4 | -491.95 Thousand USD | 17.94% |
| 2000 Q3 | -599.52 Thousand USD | -74.38% |
| 2000 FY | -911.59 Thousand USD | -13.95% |
| 2000 Q1 | -411.59 Thousand USD | -311.6% |
| 1999 Q1 | -220 Thousand USD | -46.67% |
| 1999 Q2 | 100 Thousand USD | 145.45% |
| 1999 Q3 | -100 Thousand USD | -200.0% |
| 1999 FY | -800 Thousand USD | 36.18% |
| 1999 Q4 | -100 Thousand USD | 0.0% |
| 1998 Q1 | -540 Thousand USD | -260.0% |
| 1998 Q4 | -150 Thousand USD | 37.5% |
| 1998 FY | -1.25 Million USD | 33.94% |
| 1998 Q3 | -240 Thousand USD | -4.35% |
| 1998 Q2 | -230 Thousand USD | 57.41% |
| 1997 Q2 | -210 Thousand USD | 63.16% |
| 1997 Q3 | -380 Thousand USD | -80.95% |
| 1997 FY | -1.89 Million USD | 18.95% |
| 1997 Q4 | -150 Thousand USD | 60.53% |
| 1997 Q1 | -570 Thousand USD | -72.73% |
| 1996 FY | -2.34 Million USD | 0.0% |
| 1996 Q4 | -330 Thousand USD | 51.47% |
| 1996 Q3 | -680 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | -274 Million USD | 96.995% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 93.875% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -590.767% |
| Autolus Therapeutics plc | -195.02 Million USD | 95.778% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 11.727% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 71.989% |
| Shattuck Labs, Inc. | -91.95 Million USD | 91.046% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 88.738% |
| CervoMed Inc. | -7.81 Million USD | -5.389% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 96.829% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 81.734% |
| Aptose Biosciences Inc. | -52.35 Million USD | 84.273% |
| Precision BioSciences, Inc. | -43.73 Million USD | 81.174% |
| Dyadic International, Inc. | -8.22 Million USD | -0.051% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 91.19% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 1.022% |
| Nektar Therapeutics | -137.42 Million USD | 94.008% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -26.989% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 71.857% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 88.822% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 90.54% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 96.373% |
| GRI Bio, Inc. | -11.38 Million USD | 27.69% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -82.34% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 93.724% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 31.663% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -199.217% |
| IGM Biosciences, Inc. | -263.46 Million USD | 96.875% |
| INmune Bio, Inc. | -29.74 Million USD | 72.315% |
| Opthea Limited | -191.84 Million USD | 95.708% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 86.523% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 91.787% |
| Verastem, Inc. | -92.08 Million USD | 91.058% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 82.531% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 95.529% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 93.044% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 168.949% |
| NextCure, Inc. | -67.63 Million USD | 87.826% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 59.014% |
| Organovo Holdings, Inc. | -15.08 Million USD | 45.42% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -61.76% |
| Arvinas, Inc. | -401.5 Million USD | 97.949% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 86.11% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 67.429% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 87.543% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 95.193% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 89.471% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 93.617% |
| Senti Biosciences, Inc. | -92.72 Million USD | 91.12% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 45.903% |
| Apollomics, Inc. | -54.83 Million USD | 84.984% |
| PureTech Health plc | -146.19 Million USD | 94.368% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 80.261% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 90.188% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 95.026% |
| Synaptogenix, Inc. | -8.31 Million USD | 0.961% |
| ChromaDex Corporation | -5.59 Million USD | -47.061% |
| Beam Therapeutics Inc. | -176.48 Million USD | 95.334% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 6.763% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 82.199% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 94.69% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 98.408% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -2.388% |
| Gritstone bio, Inc. | -154.63 Million USD | 94.675% |
| Mesoblast Limited | -58.79 Million USD | 85.995% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 47.52% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 81.291% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 95.678% |
| MediWound Ltd. | -15.29 Million USD | 46.148% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 95.207% |
| Fortress Biotech, Inc. | -142.34 Million USD | 94.215% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 83.803% |
| Achilles Therapeutics plc | -75.25 Million USD | 89.059% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 92.375% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 84.21% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 73.758% |
| Zai Lab Limited | -366.57 Million USD | 97.754% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -29.464% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 96.646% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 40.984% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 94.248% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 97.078% |
| Celcuity Inc. | -66.23 Million USD | 87.568% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 42.055% |
| ContextLogic Inc. | -328 Million USD | 97.49% |
| GH Research PLC | -41.22 Million USD | 80.025% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 91.572% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 67.65% |
| ImmuCell Corporation | -5.74 Million USD | -43.247% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 121.22% |
| Amarin Corporation plc | -67.58 Million USD | 87.817% |
| TG Therapeutics, Inc. | 20.63 Million USD | 139.907% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 71.487% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 88.043% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 92.369% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 67.926% |
| Aptorum Group Limited | -10.52 Million USD | 21.755% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 98.553% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 92.061% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 67.658% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 95.983% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 57.597% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 93.52% |
| Ardelyx, Inc. | -63.27 Million USD | 86.987% |
| Ainos, Inc. | -13.2 Million USD | 37.652% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 87.733% |
| Prothena Corporation plc | -191.03 Million USD | 95.69% |
| HilleVax, Inc. | -133.34 Million USD | 93.825% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 94.035% |
| Celularity Inc. | -192.28 Million USD | 95.718% |
| Rallybio Corporation | -78.93 Million USD | 89.568% |
| Cue Biopharma, Inc. | -52.14 Million USD | 84.211% |
| Omeros Corporation | -164.53 Million USD | 94.995% |
| Humacyte, Inc. | -100.04 Million USD | 91.77% |
| Immunocore Holdings plc | -59.64 Million USD | 86.196% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 55.634% |
| Blueprint Medicines Corporation | -486.27 Million USD | 98.307% |
| IO Biotech, Inc. | -91.44 Million USD | 90.996% |
| MEI Pharma, Inc. | 14.54 Million USD | 156.622% |
| GT Biopharma, Inc. | -13.57 Million USD | 39.349% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 88.971% |
| Summit Therapeutics Inc. | -89.73 Million USD | 90.824% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 75.971% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 93.738% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 95.193% |
| Pulmatrix, Inc. | -14.74 Million USD | 44.139% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 76.965% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 92.342% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 90.734% |
| Acelyrin, Inc. | -422.06 Million USD | 98.049% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 98.402% |
| Cytokinetics, Incorporated | -496.2 Million USD | 98.341% |
| Vor Biopharma Inc. | -126.03 Million USD | 93.467% |
| Evogene Ltd. | -26.39 Million USD | 68.8% |
| Replimune Group, Inc. | -234.77 Million USD | 96.493% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 87.241% |
| PDS Biotechnology Corporation | -43.04 Million USD | 80.871% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -7.042% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 98.644% |
| AEON Biopharma, Inc. | -48.42 Million USD | 82.998% |
| BioLineRx Ltd. | -49.69 Million USD | 83.431% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 78.373% |
| Atai Life Sciences N.V. | -125.47 Million USD | 93.438% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 89.886% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 75.065% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 96.693% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 73.214% |
| MediciNova, Inc. | -9.9 Million USD | 16.831% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 93.484% |
| MiMedx Group, Inc. | 37.11 Million USD | 122.184% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -13.69% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 96.448% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 97.643% |
| Mereo BioPharma Group plc | -28.41 Million USD | 71.024% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 96.419% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 70.153% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 96.6% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -71.846% |
| Allakos Inc. | -196.05 Million USD | 95.8% |
| scPharmaceuticals Inc. | -55.39 Million USD | 85.136% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 92.56% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 107.675% |
| NLS Pharmaceutics AG | -11.8 Million USD | 30.263% |
| Precigen, Inc. | -88.92 Million USD | 90.74% |
| XOMA Corporation | -41.84 Million USD | 80.324% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 92.176% |
| Incyte Corporation | 620.52 Million USD | 101.327% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 17.144% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 93.223% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 90.582% |
| Seer, Inc. | -103.46 Million USD | 92.042% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 66.125% |
| CRISPR Therapeutics AG | -222.53 Million USD | 96.3% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 95.237% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 61.642% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -0.258% |
| Akari Therapeutics, Plc | -16.8 Million USD | 51.006% |
| Novavax, Inc. | -566.51 Million USD | 98.547% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -26.016% |
| UroGen Pharma Ltd. | -65.53 Million USD | 87.436% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 90.777% |
| Entera Bio Ltd. | -8.89 Million USD | 7.39% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 67.971% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 92.826% |
| Chimerix, Inc. | -93.06 Million USD | 91.152% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 90.086% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 95.079% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 84.501% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 101.423% |
| AnaptysBio, Inc. | -164.41 Million USD | 94.992% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 46.782% |
| Portage Biotech Inc. | -18.25 Million USD | 54.89% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 92.155% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 89.725% |
| OKYO Pharma Limited | -15.74 Thousand USD | -52179.887% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 27.165% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -7.875% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 28.132% |
| AbCellera Biologics Inc. | -237.2 Million USD | 96.529% |
| Genprex, Inc. | -31.07 Million USD | 73.503% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 95.625% |
| NLS Pharmaceutics AG | -11.8 Million USD | 30.263% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -51.167% |
| Daré Bioscience, Inc. | -30.83 Million USD | 73.301% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -13.15% |
| Bicycle Therapeutics plc | -189.94 Million USD | 95.665% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 98.31% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 91.208% |
| Erasca, Inc. | -141.52 Million USD | 94.182% |
| bluebird bio, Inc. | -244.26 Million USD | 96.629% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 72.328% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 104.235% |
| DBV Technologies S.A. | -76.43 Million USD | 89.227% |
| Fortress Biotech, Inc. | -142.34 Million USD | 94.215% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 96.505% |
| CorMedix Inc. | -48.95 Million USD | 83.182% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 97.814% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 77.785% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 84.014% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 84.163% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 94.672% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 90.472% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 96.044% |
| Onconetix, Inc. | -36.03 Million USD | 77.15% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 22.049% |
| Prime Medicine, Inc. | -191.29 Million USD | 95.696% |
| Adagene Inc. | -23.71 Million USD | 65.287% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 96.244% |
| GlycoMimetics, Inc. | -39.27 Million USD | 79.035% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 73.983% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 96.31% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 106.748% |
| SciSparc Ltd. | -5.77 Million USD | -42.628% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 4.883% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 64.385% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 90.083% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 138.331% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -93012.214% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 96.585% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 43.531% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 97.082% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 19.958% |
| 2seventy bio, Inc. | -216.7 Million USD | 96.2% |
| ADMA Biologics, Inc. | 21.63 Million USD | 138.064% |
| Clene Inc. | -40.54 Million USD | 79.689% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 65.803% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 84.973% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 97.648% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 77.584% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 151.216% |
| Absci Corporation | -115.51 Million USD | 92.872% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.203% |
| Surrozen, Inc. | -45.78 Million USD | 82.014% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 92.905% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 88.717% |
| Cingulate Inc. | -22.75 Million USD | 63.821% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 209.903% |
| Jaguar Health, Inc. | -34.29 Million USD | 75.988% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 91.971% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 88.779% |
| Kronos Bio, Inc. | -121.83 Million USD | 93.241% |
| Innoviva, Inc. | 176.7 Million USD | 104.66% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 89.194% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -160.403% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 42.902% |
| Soligenix, Inc. | -7.69 Million USD | -6.963% |
| AlloVir, Inc. | -181.33 Million USD | 95.459% |
| Century Therapeutics, Inc. | -146.54 Million USD | 94.381% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 92.567% |
| Kura Oncology, Inc. | -165.8 Million USD | 95.034% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -231.794% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 90.274% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 61.041% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 78.257% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 92.556% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 78.375% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 48.471% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 47.79% |
| HCW Biologics Inc. | -25.71 Million USD | 67.983% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 94.078% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 97.017% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 95.948% |
| Lantern Pharma Inc. | -17.87 Million USD | 53.943% |
| Histogen Inc. | -10.64 Million USD | 22.635% |
| Surrozen, Inc. | -45.78 Million USD | 82.014% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 80.851% |
| Kodiak Sciences Inc. | -277.32 Million USD | 97.031% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 84.787% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 83.005% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 93.349% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 64.878% |
| Moderna, Inc. | -4.23 Billion USD | 99.806% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 97.672% |
| Turnstone Biologics Corp. | -59.03 Million USD | 86.052% |
| Immix Biopharma, Inc. | -16.14 Million USD | 48.988% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 43.549% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 91.02% |
| Exelixis, Inc. | 170.88 Million USD | 104.818% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 94.254% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 87.891% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -48.039% |
| Alkermes plc | 414.12 Million USD | 101.988% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 88.043% |
| Arcellx, Inc. | -89.88 Million USD | 90.839% |
| ESSA Pharma Inc. | -32.13 Million USD | 74.376% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 51.913% |
| Avid Bioservices, Inc. | -18.67 Million USD | 55.916% |
| Insmed Incorporated | -709.62 Million USD | 98.84% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 81.868% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 93.999% |
| Moolec Science SA | -6.65 Million USD | -23.748% |
| RenovoRx, Inc. | -11.39 Million USD | 27.747% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 86.532% |
| Geron Corporation | -193.94 Million USD | 95.754% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 80.963% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 87.479% |
| Royalty Pharma plc | 1.49 Billion USD | 100.552% |
| OmniAb, Inc. | -69.41 Million USD | 88.139% |
| Alector, Inc. | -151.74 Million USD | 94.574% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 94.984% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 95.184% |
| Humacyte, Inc. | -100.04 Million USD | 91.77% |
| Structure Therapeutics Inc. | -102.77 Million USD | 91.988% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 97.401% |
| 89bio, Inc. | -151.2 Million USD | 94.554% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 43.37% |
| Aura Biosciences, Inc. | -84.99 Million USD | 90.312% |
| Immunic, Inc. | -99.22 Million USD | 91.702% |
| Veracyte, Inc. | -85.79 Million USD | 90.403% |
| Genelux Corporation | -24.16 Million USD | 65.926% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 75.728% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -19.541% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 56.185% |
| Immunovant, Inc. | -282.7 Million USD | 97.087% |
| Vericel Corporation | -6.46 Million USD | -27.382% |
| Fortrea Holdings Inc. | 63.1 Million USD | 113.049% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 94.137% |
| XBiotech Inc. | -37.51 Million USD | 78.049% |
| Agenus Inc. | -159.54 Million USD | 94.839% |
| Acasti Pharma Inc. | -11.31 Million USD | 27.211% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 34.583% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 64.077% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 48.471% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 84.549% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 89.51% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 48.169% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 62.999% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 71.76% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 71.903% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 95.534% |
| United Therapeutics Corporation | 1.18 Billion USD | 100.695% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -46.508% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 74.903% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -61.76% |
| Silo Pharma, Inc. | -3.85 Million USD | -113.558% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -108.875% |
| Pharming Group N.V. | -4.87 Million USD | -68.744% |
| XOMA Corporation | -41.84 Million USD | 80.324% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 66.125% |
| Bionomics Limited | -17.89 Billion USD | 99.954% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 123.077% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 89.983% |
| uniQure N.V. | -282.87 Million USD | 97.089% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 89.595% |
| Cassava Sciences, Inc. | -105.95 Million USD | 92.229% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -59.74% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 53.054% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 93.642% |
| Pluri Inc. | -22.15 Million USD | 62.84% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 0.9% |
| MeiraGTx Holdings plc | -137.06 Million USD | 93.992% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 66.369% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 56.429% |
| CalciMedica, Inc. | -21.87 Million USD | 62.359% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 97.481% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 88.796% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -63754.047% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 123.077% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 87.811% |
| Nutriband Inc. | -4.87 Million USD | -69.008% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 81.12% |
| Compugen Ltd. | -12.99 Million USD | 36.623% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.194% |
| ProKidney Corp. | -151.52 Million USD | 94.566% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -81.886% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -124.415% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 92.788% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 89.914% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 83.401% |
| Benitec Biopharma Inc. | -22.49 Million USD | 63.388% |
| GeoVax Labs, Inc. | -26.74 Million USD | 69.211% |
| Biomea Fusion, Inc. | -126.13 Million USD | 93.472% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 95.691% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 92.705% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 67.32% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 64.039% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 96.602% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 96.041% |
| Imunon, Inc. | -21.03 Million USD | 60.847% |
| BioAtla, Inc. | -129.68 Million USD | 93.651% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 97.488% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 80.282% |
| Zura Bio Limited | -62.63 Million USD | 86.855% |
| aTyr Pharma, Inc. | -54.91 Million USD | 85.007% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 97.836% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 96.764% |
| Galecto, Inc. | -39.9 Million USD | 79.366% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -93012.214% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 102.439% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 95.206% |
| PolyPid Ltd. | -22.86 Million USD | 63.992% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 49.411% |
| Forte Biosciences, Inc. | -32.48 Million USD | 74.654% |
| Xencor, Inc. | -138.63 Million USD | 94.061% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 61.687% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -26.016% |
| Instil Bio, Inc. | -159.16 Million USD | 94.827% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -13.69% |
| OncoCyte Corporation | -25.13 Million USD | 67.242% |
| Elevation Oncology, Inc. | -45.44 Million USD | 81.882% |
| Purple Biotech Ltd. | 22.27 Million USD | 136.972% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -9.611% |
| MacroGenics, Inc. | -168.24 Million USD | 95.106% |
| Verona Pharma plc | -67.83 Million USD | 87.861% |
| Tharimmune, Inc. | -9.45 Million USD | 12.916% |
| Apogee Therapeutics, Inc. | -93 Million USD | 91.147% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 68.404% |
| Aditxt, Inc. | -26.06 Million USD | 68.407% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -976.332% |
| Savara Inc. | -60 Million USD | 86.278% |
| Curis, Inc. | -48.33 Million USD | 82.964% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -57.821% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 69.784% |
| BeiGene, Ltd. | -1.2 Billion USD | 99.318% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -81.886% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 80.676% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 38.188% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 87.754% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 59.817% |
| Adicet Bio, Inc. | -152.03 Million USD | 94.584% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -12.638% |
| Quantum-Si incorporated | -111.17 Million USD | 92.593% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 43.517% |
| Generation Bio Co. | -138.56 Million USD | 94.058% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 90.477% |
| Invivyd, Inc. | -207.78 Million USD | 96.037% |
| Relay Therapeutics, Inc. | -373 Million USD | 97.793% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 12.204% |
| Moolec Science SA | -6.65 Million USD | -23.748% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 66.857% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 85.493% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 92.06% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 95.164% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 98.797% |
| Evaxion Biotech A/S | -22.19 Million USD | 62.905% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 90.005% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 89.7% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 81.566% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 86.735% |
| Clearmind Medicine Inc. | -8.74 Million USD | 5.805% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 88.553% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 109.485% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -180.736% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 91.834% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 95.155% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 96.301% |
| ImmunityBio, Inc. | -362.25 Million USD | 97.727% |
| Korro Bio, Inc. | -84.53 Million USD | 90.26% |
| Kineta, Inc. | -15.72 Million USD | 47.631% |
| BioVie Inc. | -32.17 Million USD | 74.413% |
| Codexis, Inc. | -68.06 Million USD | 87.904% |
| Celularity Inc. | -192.28 Million USD | 95.718% |
| Virax Biolabs Group Limited | -6.49 Million USD | -26.745% |
| Cibus, Inc. | -318.88 Million USD | 97.418% |
| Annexon, Inc. | -143.72 Million USD | 94.271% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 87.263% |
| Eyenovia, Inc. | -25.4 Million USD | 67.591% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 125.227% |
| NeurAxis, Inc. | -6.66 Million USD | -23.549% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 73.532% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 83.651% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 62.393% |
| Notable Labs, Ltd. | -14.65 Million USD | 43.822% |
| IN8bio, Inc. | -30.33 Million USD | 72.858% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 61.283% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 91.928% |
| Lumos Pharma, Inc. | -36.61 Million USD | 77.511% |
| Liquidia Corporation | -73.38 Million USD | 88.78% |
| Mustang Bio, Inc. | -50.72 Million USD | 83.768% |
| Quantum-Si incorporated | -111.17 Million USD | 92.593% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 89.458% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 68.404% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 87.805% |
| 180 Life Sciences Corp. | -13.47 Million USD | 38.906% |
| Vaxcyte, Inc. | -468.04 Million USD | 98.241% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 96.153% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -12.638% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 72.319% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 259.687% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -180.736% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 80.104% |
| PepGen Inc. | -84.76 Million USD | 90.286% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 72.212% |
| Solid Biosciences Inc. | -104.31 Million USD | 92.107% |
| Palisade Bio, Inc. | -13.07 Million USD | 37.001% |
| Nutriband Inc. | -4.87 Million USD | -69.008% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -48.039% |
| Immuneering Corporation | -58.41 Million USD | 85.904% |
| Belite Bio, Inc | -31.66 Million USD | 73.999% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 85.15% |
| GeoVax Labs, Inc. | -26.74 Million USD | 69.211% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 81.867% |
| Altimmune, Inc. | -95.92 Million USD | 91.417% |
| Peak Bio, Inc. | -1356.23 USD | -607019.81% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 42.055% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 7.369% |
| Neurogene Inc. | -55.58 Million USD | 85.186% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 92.457% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 3.142% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 91.486% |
| Sesen Bio, Inc. | -25.9 Million USD | 68.22% |
| argenx SE | -425.04 Million USD | 98.063% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 72.319% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 82.908% |
| Immunome, Inc. | -109.53 Million USD | 92.482% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 49.941% |
| Design Therapeutics, Inc. | -78.19 Million USD | 89.469% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 79.669% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 90.142% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 98.212% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 88.633% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 93.911% |
| Athira Pharma, Inc. | -125.46 Million USD | 93.437% |
| XOMA Corporation | -41.84 Million USD | 80.324% |
| Merus N.V. | -156.54 Million USD | 94.74% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 76.216% |
| Rezolute, Inc. | -70.42 Million USD | 88.308% |
| Clene Inc. | -40.54 Million USD | 79.689% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 49.727% |
| BeyondSpring Inc. | -23.11 Million USD | 64.377% |
| Synlogic, Inc. | -55.16 Million USD | 85.073% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 54.075% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 23.929% |
| Peak Bio, Inc. | -1356.23 USD | -607019.81% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 79.671% |
| Krystal Biotech, Inc. | -109.72 Million USD | 92.496% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 93.644% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 97.6% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -73.494% |
| MannKind Corporation | 8.67 Million USD | 194.883% |
| Ikena Oncology, Inc. | -75.41 Million USD | 89.082% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 14.648% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 87.753% |
| Gossamer Bio, Inc. | -183.75 Million USD | 95.519% |
| CohBar, Inc. | -12.38 Million USD | 33.535% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 83.767% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 70.153% |
| Legend Biotech Corporation | -439.48 Million USD | 98.126% |
| Mural Oncology plc | -194.63 Million USD | 95.77% |
| Disc Medicine, Inc. | -91.12 Million USD | 90.964% |
| Champions Oncology, Inc. | -7.35 Million USD | -11.935% |
| REGENXBIO Inc. | -268.12 Million USD | 96.929% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 23.178% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 85.232% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 78.866% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 92.8% |
| Vaxart, Inc. | -83.34 Million USD | 90.121% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 3.358% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 80.759% |
| Cellectis S.A. | -106.62 Million USD | 92.278% |
| Longeveron Inc. | -21.02 Million USD | 60.845% |
| Repare Therapeutics Inc. | -116.22 Million USD | 92.915% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 96.926% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 89.115% |
| Revolution Medicines, Inc. | -487.18 Million USD | 98.31% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -23.781% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 81.267% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 88.961% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 88.176% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 25.221% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.191% |
| Denali Therapeutics Inc. | -196.69 Million USD | 95.814% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 4.883% |
| Veru Inc. | -93.78 Million USD | 91.22% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 64.705% |
| Cingulate Inc. | -22.75 Million USD | 63.821% |
| Passage Bio, Inc. | -108.38 Million USD | 92.403% |
| Context Therapeutics Inc. | -25.07 Million USD | 67.16% |
| Exicure, Inc. | -14.99 Million USD | 45.092% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 96.004% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 79.718% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 15.262% |
| Nuvalent, Inc. | -149.49 Million USD | 94.492% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -0.212% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 90.72% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 60.364% |
| OmniAb, Inc. | -69.41 Million USD | 88.139% |
| Anew Medical, Inc. | -1.3 Million USD | -532.971% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 35.526% |
| Lipocine Inc. | -17.93 Million USD | 54.08% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 87.982% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 89.187% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 78.375% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 79.169% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 63.215% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 98.58% |
| Ocugen, Inc. | -65.53 Million USD | 87.435% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 91.228% |
| Q32 Bio Inc. | -92.1 Million USD | 91.06% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 61.594% |
| Alumis Inc. Common Stock | -158.17 Million USD | 94.794% |
| Equillium, Inc. | -14.52 Million USD | 43.3% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 86.806% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -4.183% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 56.354% |
| Dominari Holdings Inc. | -21.79 Million USD | 62.223% |
| Edesa Biotech, Inc. | -9.22 Million USD | 10.721% |
| vTv Therapeutics Inc. | -25.5 Million USD | 67.713% |
| Bio-Techne Corporation | 206.68 Million USD | 103.984% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 97.897% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 104.288% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 93.775% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 78.552% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 94.551% |
| Nkarta, Inc. | -131.65 Million USD | 93.746% |
| BioCardia, Inc. | -11.64 Million USD | 29.286% |
| Iterum Therapeutics plc | -47.46 Million USD | 82.654% |